Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase...
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
About this item
Full title
Author / Creator
Subbiah, Vivek , Cassier, Philippe A. , Siena, Salvatore , Garralda, Elena , Paz-Ares, Luis , Garrido, Pilar , Nadal, Ernest , Vuky, Jacqueline , Lopes, Gilberto , Kalemkerian, Gregory P. , Bowles, Daniel W. , Seetharam, Mahesh , Chang, Jianhua , Zhang, Hui , Green, Jennifer , Zalutskaya, Alena , Schuler, Martin , Fan, Yun and Curigliano, Giuseppe
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Oncogenic
RET
fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW (
NCT03037385
, ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced
RET
-altered solid tumors. Twenty-nine patients with 12 different
RET
fusion–positive...
Alternative Titles
Full title
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Authors, Artists and Contributors
Author / Creator
Cassier, Philippe A.
Siena, Salvatore
Garralda, Elena
Paz-Ares, Luis
Garrido, Pilar
Nadal, Ernest
Vuky, Jacqueline
Lopes, Gilberto
Kalemkerian, Gregory P.
Bowles, Daniel W.
Seetharam, Mahesh
Chang, Jianhua
Zhang, Hui
Green, Jennifer
Zalutskaya, Alena
Schuler, Martin
Fan, Yun
Curigliano, Giuseppe
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9388374
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9388374
Other Identifiers
ISSN
1078-8956,1546-170X
E-ISSN
1546-170X
DOI
10.1038/s41591-022-01931-y
